- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07831291
Childhood Obesity Risk Markers (MARIOBE) (MARIOBE)
Childhood Obesity Risk Markers
Metabolic diseases, including childhood obesity, represent a major public health challenge. Studies in mice have identified transcriptomic markers in adipose tissue capable of predicting a predisposition to obesity prior to any weight gain. The MARIOBE project aims to translate this approach to young children (≤ 4 years old) in order to identify individual vulnerability to obesity at an early stage.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lise Laclautre
- Phone Number: +334754963
- Email: promo_interne_drci@chu-clermontferrand.fr
Study Locations
-
-
-
Clermont-Ferrand, France, 63000
- CHU de Clermont-Ferrand
-
Contact:
- Lise Laclautre
- Phone Number: +33473754963
- Email: promo_interne_drci@chu-clermontferrand.fr
-
Principal Investigator:
- Etienne Merlin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Child scheduled for surgery allowing for the harvesting of adipose tissue.
Exclusion Criteria:
- Child whose holders of parental authority are protected by law
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: early transcriptomic markers
|
during a scheduled surgery before the age of 4 years, collection of a blood sample (2.5 mL in a PAXgene tube) and two adipose tissue fragments, each measuring 5 mm x 5 mm x 5 mm. tracking of weight and height curves from birth to age 6 |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
transcriptomic markers in children under 4 years of age that predict a predisposition to being overweight at age 6 (BMI > IOTF25).
Time Frame: perioperative
|
Ranking of the discriminative capacity of adipocyte and blood transcripts before 4 years of age to predict the development of overweight (BMI > IOTF25) at age 6, using Partial Least Squares Discriminant Analysis (PLS-DA). |
perioperative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
analyze weight trajectories
Time Frame: at age 6 years
|
Selection and validation of transcriptomic markers for the development of a predictive score for the risk of overweight and obesity in children |
at age 6 years
|
|
molecular and epigenetic mechanisms associated with the identified transcriptomic signatures.
Time Frame: at the time of blood ans adipose tissu sampling
|
methylation profiles |
at the time of blood ans adipose tissu sampling
|
|
comparison of transcriptomic expression levels between blood and adipose tissue
Time Frame: perioperative
|
percentage of common markers sampled from blood and adipose tissue |
perioperative
|
|
develop a quantitative test based on digital PCR to define individual expression thresholds predictive of risk
Time Frame: at age 6 years
|
Performance of the digital PCR test evaluated by the ability to discriminate weight trajectories (AUC of ROC curves). |
at age 6 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Etienne Merlin, University Hospital, Clermont-Ferrand
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RBHP 2026 MERLIN
- 2026-A00633-48 (Other Identifier: ANSM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.